Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

Nishida, Sumiyuki; Koido, Shigeo; Takeda, Yutaka; Homma, Sadamu; Komita, Hideo; Takahara, Akitaka; Morita, Satoshi; Ito, Toshinori; Morimoto, Soyoko; Hara, Kazuma; Tsuboi, Akihiro; Oka, Y.; Yanagisawa, Satoru; Toyama, Yoichi; Ikegami, Machiko; Kitagawa, Toru; Eguchi, Hidetoshi; Wada, Hiroshi; Nagano, Hiroaki; Nakata, Jun; Nakae, Yoshiki; Hosen, Naoki; Oji, Yusuke; Tanaka, Toshio; Kawase, Ichiro; Kumanogoh, Atsushi; Sakamoto, Junichi; Doki, Yuichiro; Mori, Masaki; Ohkusa, Toshifumi; Tajiri, Hisao; Sugiyama, Haruo

doi:10.1097/cji.0000000000000020

Cited by 79 publications

(65 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,11), and has been found to be both oncogenic during tumorigenesis (12) and immunogenic (13)(14)(15). Therefore, other groups and our laboratory have performed clinical studies investigating the efficacy of immunotherapies targeting WT1 using a MHC-I restricted peptide for patients with PDA (16,17). Recently, MHC class II (MHC-II) epitopes derived from WT1 have been made available for use in clinical trials (18,19).…”

Section: Introductionmentioning

confidence: 99%

Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer

Koido

Homma²,

Okamoto

et al. 2014

Clinical Cancer Research

Self Cite

115

112

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer

Koido

Homma²,

Okamoto

et al. 2014

Clinical Cancer Research

Self Cite

115

112

View full text Add to dashboard Cite

show abstract

“…AWT1 peptide based vaccine in advanced pancreatic cancer, when combined with gemcitabine showed a 29% 1 year survival and a median survival of 8.1 months [26]. Another peptide based vaccine used E75 derived from the HER2 protein (nelipepimut-S) along with GMCSF as an adjuvant for treatment of breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Cancer Vaccines: Bench to Bedside

Tuli

Maniyar

Bednarczyk

et al. 2016

IJTS

View full text Add to dashboard Cite

The immune system has immense potential in cancer therapy as it is individualized, precision driven and robust, however, it is associated with challenges of its own that include immune evasion, development of tolerance and a sustained tumor rejection response. Recent FDA approval of several checkpoint inhibitors, anti-CTLA4, anti-PD-1, has re-invigorated cancer immunology by demonstrating that tolerance to cancer can be broken to induce a sustained immune response in patients. Active immunization with multivalent tumor associated antigens (TAA), however, is still a challenge. We have developed two specific distinct methods to generate multivalent antigens capable of tumor regression in prostate cancer and melanoma. In prostate cancer, we have generated specific multivalent peptide mimetics using phage display synthetic peptide libraries capable of metastatic tumor regression in an animal model. In melanoma, we have used a vaccinia virus based antigen retrieval technology to generate a multivalent antigenic vaccine. The antigenic repertoire is well defined. A protocol for the melanoma vaccine is FDA approved for clinical Science, Vol. 2016, 33-60. doi: 10.13052/ijts2246-8765.2016.003 c 2016 34 N. Tuli et al. trials. We envision defining the humoral and cellular immune response to combine our active vaccine strategy with other treatment modalities including approved checkpoint inhibitors anti-CTLA4 and anti-PD-1. We believe our vaccine candidates are a new generation of immune-therapeutics that can prolong cancer free survival and prevent secondary recurrences. Our studies have challenged the existing paradigms to re-define cancer immunotherapy that bridges the gap between humoral and cellular immunity by combining active immune response with negative checkpoint inhibitors thus activating pre-existing dormant immune response. International Journal of Translational

show abstract

“…152 CMPs represent a novel approach to harness non-protein TAAs for the activation of tumor-specific immunity. [153][154][155] Patients affected by virtually all types of neoplasms have been enrolled in these clinical trials, including (but not limited to) various hematological malignancies, which is highly expressed by a wide panel of malignancies; [173][174][175] Wilms' tumor 1 (WT1), 90,111,122,125 which is expressed to elevated levels by (at least some variants of) colorectal carcinoma, melanoma, acute myeloid leukemia. [176][177][178][179] In addition, several of these trials tested the safety and therapeutic activity of mixtures comprising up to 12-15 distinct TAA-derived peptides, 91,100,102,103,105,106,113,120,121,123,124,[128][129][130]133,136,140,141,147,150 or "personalized peptide vaccination" (PPV), i.e., the administration of one or more peptides derived from TAAs against which the patient have previously (naturally or in response to other therapies) developed an immune response.…”

Section: Literature Updatementioning

confidence: 99%